Navigation Links
Hovione Appoints Terry Lambe to its Board of Directors

CORK, Ireland, September 10 /PRNewswire/ -- Hovione announced today that Terry Lambe, Ph.D., has been elected to the Board of Directors of Hovione Ltd.

Hovione acquired earlier this year an important API manufacturing site located in Cork. This is a key element of the Hovione strategy to become a leading manufacturer to the pharmaceutical industry.

"We are delighted to welcome Terry Lambe to Hovione. We want to build our Cork site into the ideal, preferred, launch facility for new product introductions. In the context of the emerging business model based on outsourcing, our Cork site provides innovator pharmaceutical companies with all the benefits of a top manufacturing facility without the costs of ownership. Terry has a good understanding of what Large Pharma requires and brings to Hovione a wealth of international experience in manufacturing activities. We also feel that to do this right it is important to have on the board of our subsidiary company in Ireland someone familiar with the local culture and with strong links into the Irish pharmachem industry," said Guy Villax, Hovione's Chief Executive. In addition Terry also becomes a member of the Hovione Manufacturing Committee that sets out the longer-term production strategy for the group.

"I am enthusiastic about joining a successful and dynamic company like Hovione and I hope to be able to make a significant contribution to its profitable growth," said Dr. Lambe.

Dr. Terry Lambe joins Hovione following his retirement from Pfizer Inc. in 2008. Dr. Lambe worked at Pfizer for 30 years, during this time he held roles of increasing responsibility in manufacturing and was responsible for the construction of several API facilities in Puerto Rico, in Groton, Connecticut and later in Singapore. In 1999, Dr. Lambe assumed his role as Vice President, Global Drug Substance. In 2000, he was appointed Team Leader / Vice President, Ireland / Singapore Manufacturing Area, a position he held until 2008. In 2004, Dr. Lambe was awarded the Bio-Link USA - Ireland Life Science Award for his contribution to the Pharmaceutical Industry. He holds a B.S. and a Ph.D. in Chemistry from University College Cork and completed a post-doctoral fellowship in Electro-Fluorination Chemistry at the University of Manchester.

About Hovione

Hovione is an international company with 50 years' experience in active pharmaceutical ingredient development and compliant manufacture. With four FDA inspected sites in the US, China, Ireland and Portugal the company focuses on the most demanding customers in the most highly regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area Hovione is the only independent company offering such a broad range of services.

For more information about Hovione, please visit the Hovione site at or contact Corporate Communications, Isabel Pina, +351-21-982-9362, e-mail:

SOURCE Hovione
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Inspects Hoviones API Manufacturing Plant in Macau
2. Hovione Opens its New API Plant in Cork
3. Hoviones TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza
4. Hovione Buys Pfizers Loughbeg API Facility
5. Hoviones Sales Grow 11%
6. Hovione Launches New Website
7. Hovione Buys Drug Manufacturing Facility in China
8. Sechrist Increases Focus on International Markets; Appoints William Preuit Senior Vice President
9. China Biologic Products Appoints Director of Research and Development
10. PriceSpective Appoints Colasante as a Vice President and Murdoch as a Director
11. iPierian Appoints Dr. Matthew J. Plunkett as Chief Financial Officer
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... featured on AngelList early in their initial angel funding process. Now, they are ... individuals looking to make early stage investments in the microbiome space. In ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
(Date:11/24/2015)... November 24, 2015 --> ... research report "Oligonucleotide Synthesis Market by Product & Services ... Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, ... MarketsandMarkets, the market is expected to reach USD 1,918.6 ... at a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
Breaking Biology Technology:
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):